ArticleCureus2026
Real-World Feasibility of Fibrosis-4-Based Fibrosis Risk Stratification in Patients With Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among patients with type 2 diabetes mellitus (T2DM), a population at increased risk for advanced liver fibrosis. Current guidelines recommend the Fibrosis-4 (FIB-4) index as a first-line fibrosis risk stratification tool; however, its implementation in routine clinical practice remains uncertain. Aim To evaluate the real-world feasibility of FIB-4-based fibrosis risk stratification in patients with T2DM and MASLD. Methods We conducted a retrospective cross-sectional study including adult outpatients with T2DM and MASLD evaluated at a national referral center in Santo Domingo, Dominican Republic, between March 2022 and January 2025. Feasibility was defined as the proportion of patients with sufficient laboratory data to calculate FIB-4. Results A total of 397 patients were included. Only 143 patients (36.0%) had complete laboratory data required for FIB-4 calculation, while 254 (64.0%) lacked at least one required variable. AST and ALT were the most frequently missing laboratory parameters. Among patients with calculable FIB-4 values, 16 (11.2%) were classified as high risk for advanced fibrosis according to age-adjusted thresholds. Conclusions In this real-world cohort of patients with T2DM and MASLD, guideline-recommended FIB-4-based fibrosis risk stratification showed limited feasibility due to incomplete routine laboratory data. These findings highlight opportunities to improve the integration of standardized fibrosis risk assessment into routine diabetes care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.